Medrx Co.,Ltd.
4586 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 東かがわ市西山４３１番地７
- Website:
- https://www.medrx.co.jp/english/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Medrx Co., Ltd. is a pioneering pharmaceutical formulation development company based in Japan, dedicated to enhancing global health and quality of life. By leveraging advanced drug formulation technologies, including innovative transdermal absorption methods, Medrx focuses on creating groundbreaking new medications. Their mission is to develop novel dosage forms that optimize medication adherence, particularly for patients who face challenges with traditional oral administration. Committed to pharmaceutical innovation, Medrx strives to transform the way medications are delivered, ensuring that effective treatments are accessible and easy to use for all patients.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-13 08:31 |
Inside Information Statement
臨時報告書
|
Japanese | 39.1 KB | |
| 2025-03-31 08:33 |
Internal Control over Financial Reporting
内部統制報告書－第23期(2024/01/01－2024/12/31)
|
Japanese | 23.9 KB | |
| 2025-03-31 08:32 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2025-03-31 08:32 |
Inside Information Statement
臨時報告書
|
Japanese | 25.0 KB | |
| 2025-03-31 08:32 |
Regulatory News Service
訂正有価証券届出書（組込方式）
|
Japanese | 271.6 KB | |
| 2025-03-31 08:31 |
Annual Report
有価証券報告書－第23期(2024/01/01－2024/12/31)
|
Japanese | 1.4 MB | |
| 2025-03-28 07:31 |
Regulatory News Service
訂正有価証券届出書（組込方式）
|
Japanese | 268.0 KB | |
| 2025-03-25 07:31 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 409.6 KB | |
| 2024-08-09 08:01 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2024-08-09 08:00 |
Interim Report
半期報告書－第23期(2024/01/01－2024/12/31)
|
Japanese | 345.0 KB | |
| 2024-05-17 08:01 |
Inside Information Statement
臨時報告書
|
Japanese | 39.2 KB | |
| 2024-05-10 08:02 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2024-05-10 08:01 |
Quarterly Report
四半期報告書－第23期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 408.3 KB | |
| 2024-03-29 07:12 |
Inside Information Statement
臨時報告書
|
Japanese | 33.5 KB | |
| 2024-03-29 07:10 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Cuorips Inc. | Japan | 4894 | |
|
Cyfuse Biomedical K.K. | Japan | 4892 | |
|
DAIICHI SANKYO COMPANY, LIMITED | Japan | 4568 | |
|
Daito Pharmaceutical Co., Ltd. | Japan | 4577 | |
|
DanCann Pharma A/S | Denmark | DANCAN | |
|
DARWIN AG | Germany | 7V0 | |
|
Dechra Pharmaceuticals PLC | United Kingdom | DPH | |
|
Delta-Fly Pharma, Inc. | Japan | 4598 | |
|
Dermapharm Holding SE | Germany | DMP | |
|
Dicot Pharma AB | Sweden | DICOTBT |